Portable's mobile app allows patients to capture genotype, phenotype, and other data, and potentially profit from sharing it with interested third parties.
Researchers from Brigham and Women's and Harvard surveyed more than 1,600 new customers of 23andMe or Pathway Genomics in the US, of whom 80 were adopted.
The partnerships are in the areas of consumer applications in reproductive health, and genetics-focused educational programs and entrepreneurship support.
The availability of consumer genomics services has also made it possible for adoptees to bypass state adoption laws, many of which restrict access to their records.
The test, called CancerIntercept Detect, is aimed at the early discovery of malignancies in asymptomatic people with an elevated risk of developing cancer, and can be ordered directly through Pathway and its online doctor network.
The company, called Helix, has received commitments for more than $100 million in financing and has signed on the Mayo Clinic and LabCorp as initial partners.
23andMe has seen a rebound in its ancestry testing business, and hopes that it will be able to return health information to US customers by the year end.
Thanks to a new array, NatGeo will now offer customers expanded Y chromosome and mtDNA analyses, setting it apart in a competitive consumer genomics market.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.
